glp 1 drugs alzheimer's disease: Semaglutide use linked to lower risk Novo Nordisk still sees potential
Description
pooling data for lixisenatide (Adlyxin, Sanofi), liraglutide (Victoza,
RELIEVES THE 4 WORST GLP-1 SIDE EFFECTS IN ONE FORMULA Constipation that lasts 46 days
Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions
In the subgroup analyses, human GLP-1 RAs, but not nonhuman GLP-1 RAs, reduced the risk of MACE in patients with HF (p interaction = 0.11)
Results The first cohort included 36082 GLP-1 receptor agonist users (median follow-up 1.3 years) and 234028 DPP-4 inhibitor users (median follow-up 1.7 years)
